buy sell hold 

 

UOB KAYHIAN DBS VICKERS 

Sembcorp Industries (SCI SP)

Well Positioned For Recovery In 2021

 

We believe SCI is well positioned for recovery in 2021. This comes as news of successful vaccine trials has led to higher certainty that the global economic recovery may be swifter than expected, thus positively impacting energy demand. The company currently trades at 0.7x 2021F P/B, which is undemanding in our view. Maintain BUY with higher target price of S$2.02 (previously S$1.66).

 

Read More ...

 

OCBC

Share price to see support

Investment Thesis

Inexpensive valuation; ongoing provisioning provides buffer.

 

OCBC’s share price has gained >10% since early November, when it was trading near trough valuations. We believe there is further room for OCBC’s share price to re-rate amidst expectations of a gradual pick-up in long-end yields, as OCBC is seen as a proxy to economic recovery. OCBC’s strong NPA coverage of 109% (2Q20: 101%) and ongoing provisioning of S$1.8bn as of 9M20 will limit downside risks. While there may be further NIM headwinds into 4Q20 as OCBC’s loan book continues to reprice, we believe its strength in non-interest income franchise should continue to contribute positively, providing some income support for FY21F.

 

Read More ...

DBS VICKERS 

 CGS-CIMB

UOB

Ongoing provisioning is a buffer

Investment Thesis

Inexpensive valuation; ongoing provisioning is a buffer.

 

Even after share price gaining >10% since early November, we believe there is further room to re-rate amid expectations of a gradual pick up in long-end yields. We see UOB as a proxy to economic recovery. It’s strong non-performing asset (NPA) coverage of 111% (2Q20: 96%) and ongoing provisioning (management guides for S$2-3bn through FY20-21F) will limit downside risks. Management has guided for better-than-expected asset quality outlook during 3Q20 results briefing.

 

Read More ...

Singapore Airlines

The path to recovery is not a straight line


 ■ The postponement of the SIN-HKG travel bubble is disappointing but is likely part of a series of stops and starts on the arduous road to recovery.

■ Patient investors with a 1-year horizon should be able to reap the rewards of upcoming Covid-19 vaccinations; we recommend to buy on any dips.

■ Reiterate Add and TP of S$4.57, based on a target P/BV multiple of 0.94x (mean since 2011) against the end-FY22F adjusted BVPS.


Read more....


LionelLim8.16Check out our compilation of Target Prices




Share Prices

Counter NameLastChange
AEM Holdings3.700-0.100
Avi-Tech Electronics0.280-
Best World1.760-0.030
Broadway Ind0.120-
China Sunsine0.395-0.010
DISA0.003-
Food Empire0.640-
Fortress Minerals0.375-
Geo Energy Res0.3550.005
Golden Energy0.7950.005
GSS Energy0.048-0.001
InnoTek0.460-0.010
ISDN Holdings0.400-0.005
ISOTeam0.090-
IX Biopharma0.125-0.002
Jiutian Chemical0.080-
KSH Holdings0.350-
Leader Env0.056-
Medtecs Intl0.136-0.002
Meta Health0.025-
Nordic Group0.465-0.010
Oxley Holdings0.151-
REX International0.225-0.010
Riverstone0.6250.010
Sinostar PEC0.185-0.010
Southern Alliance Mining0.410-0.090
Straco Corp.0.395-
Sunpower Group0.2750.005
The Trendlines0.092-0.001
Totm Technologies0.102-
UG Healthcare0.190-0.004
Uni-Asia Group0.810-
Wilmar Intl4.050-0.040
Yangzijiang Shipbldg1.380-0.020

NextInsight RSS

rss_2 NextInsight - Latest News

Online Now

We have 459 guests and no members online